AB Science a reçu le
AB Science a reçu les premières autorisations règlementaires pour initier une étude clinique confirmatoire de phase 3 avec le masitinib dans le traitement de la maladie d’Alzheimer
October 10, 2022 12:04 ET | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A REÇU LES PREMIÈRES AUTORISATIONS RÈGLEMENTAIRES POUR INITIER UNE ÉTUDE CLINIQUE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LE TRAITEMENT DE LA MALADIE...
AB Science receives
AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease
October 10, 2022 12:04 ET | AB Science
PRESS RELEASE AB SCIENCE RECEIVES FIRST AGENCIES AUTHORIZATIONS TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris, October 10th 2022, 6pm...
Equillium_Square_Logo.png
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights
November 10, 2020 16:05 ET | Equillium
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
AB Science présenter
AB Science présentera les résultats de son étude de phase 3 dans l’asthme sévère au Congrès Annuel International de European Respiratory Society
September 08, 2020 02:44 ET | AB Science
Paris, 8 septembre 2020, 7h30 AB Science présentera les résultats de son étude de phase 3 dans l’asthmesévère au Congrès Annuel International de European Respiratory Society  ...
AB Science to presen
AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congress
September 08, 2020 02:44 ET | AB Science
Paris, 08 September 2020, 7.30am AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congress Abstract...
Equillium_Square_Logo.png
Equillium to Present at BTIG Virtual Biotechnology Conference 2020
July 30, 2020 16:07 ET | Equillium
LA JOLLA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium_Square_Logo.png
Equillium to Present at Jefferies Virtual Healthcare Conference
May 21, 2020 16:07 ET | Equillium
LA JOLLA, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium_Square_Logo.png
Equillium Reports First Quarter 2020 Financial Results
May 13, 2020 16:07 ET | Equillium
LA JOLLA, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium_Square_Logo.png
Equillium to Present at 2020 RBC Capital Markets Virtual Global Healthcare Conference
May 07, 2020 16:07 ET | Equillium
LA JOLLA, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Lettre aux partenair
Lettre aux partenaires d'AB Science concernant l’impact de la pandémie COVID-19 sur les études cliniques d’AB Science
April 07, 2020 12:33 ET | AB Science
Paris, 7 avril 2020, 18h15 Lettre à nos partenaires concernant l’impact de la pandémie COVID-19 sur lesétudes cliniques d’AB Science     Chers partenaires, À l'heure actuelle, nous prévoyons que...